Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:58 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 283 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Percutaneous Coronary Intervention Clear all

Conditions: Coronary Artery Disease
Interventions: Not listed
Lead sponsor: CoreAalst BV; Industry
Eligibility: 21 Years and older
Enrollment: 888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Stanford, California • Decatur, Georgia • Bangor, Maine

Conditions: Diabetes Mellitus, Type 2, Coronary Artery Disease
Interventions: Ticagrelor monotherapy, Ticagrelor plus aspirin, Clopidogrel with aspirin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Coronary Angiography, Radial Artery Occlusion
Interventions: Not listed
Lead sponsor: Jesse Brown VA Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Total Occlusion, Occlusion
Interventions: Chronic total occlusion percutaneous coronary intervention; Procedure
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Percutaneous Coronary Intervention
Interventions: PEP; Drug
Lead sponsor: Christopher J. McLeod; Other
Eligibility: 21 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronary Artery Disease (CAD)
Interventions: M118, Unfractionated Heparin; Drug
Lead sponsor: Momenta Pharmaceuticals, Inc.; Industry
Eligibility: 19 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 37
States / cities: Little Rock, Arkansas • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 33 more

Conditions: Percutaneous Coronary Intervention
Interventions: FFRangio, FFR or NHPR; Device
Lead sponsor: CathWorks Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 1,924 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: La Jolla, California • Long Beach, California • Los Angeles, California + 34 more

Conditions: Acute Coronary Syndrome, Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin, Plavix (clopidogrel 75 mg) and aspirin; Drug
Lead sponsor: Cogentus Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 247
States / cities: Alexander City, Alabama • Birmingham, Alabama • Geneva, Alabama + 205 more

Conditions: Coronary Artery Disease, Percutaneous Coronary Intervention
Interventions: Percutaneous coronary intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Myocardial Infarction
Interventions: KAI-9803 for Injection, Placebo; Drug
Lead sponsor: KAI Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Stable Angina
Interventions: Intravenous Glycoprotein inhibitor + ASA, Clopidogrel, Antiplatelet Therapy (ASA, Clopidogrel); Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Myocardial Reperfusion Injury
Interventions: BQ-123, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronary Artery Disease
Interventions: Ticagrelor 90 mg, Prasugrel 10 mg; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Coronary Artery Disease, Coronary Disease, Myocardial Ischemia, Heart Diseases, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Vascular Diseases
Interventions: CorPath robotic-assisted PCI; Device
Lead sponsor: Siemens Healthineers Endovascular Robotics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Washington D.C., District of Columbia • Gainesville, Georgia • Boston, Massachusetts + 5 more

Conditions: Percutaneous Coronary Intervention, Valve Repair/Replacement, Coronary Artery Bypass Grafting
Interventions: EHR Nudges; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Myocardial Infarction, Angina, Coronary Artery Disease, Myocardial Ischemia
Interventions: Intravascular Near Infrared Spectroscopy; Device
Lead sponsor: Infraredx; Industry
Eligibility: 18 Years and older
Enrollment: 2,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 22
States / cities: Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more

Conditions: Coronary Arteriosclerosis, Non ST Segment Elevation Acute Coronary Syndrome
Interventions: OrbusNeich Combo stent™, Everolimus Eluting Stent (EES); Device
Lead sponsor: OrbusNeich; Industry
Eligibility: 20 Years and older
Enrollment: 572 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 17
States / cities: Washington D.C., District of Columbia • Lake Worth, Florida • Miami, Florida + 14 more

Conditions: Physical Activity
Interventions: Physical Activity Promotion Intervention; Behavioral
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 2
States / cities: Lincoln, Nebraska

Conditions: Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases, Thrombocytopenia, Coagulation Disorder, Anemia, Renal Insufficiency, Coronary Artery Disease
Interventions: XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor); Device · Drug
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 1,605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 54
States / cities: Huntsville, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 47 more

Conditions: Acute Myocardial Infarction
Interventions: INO-1001; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 10
States / cities: Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more

Conditions: Cardiovascular Disease
Interventions: Exercise Therapy; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 45 Years to 75 Years
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Coronary Artery Disease (CAD)
Interventions: Orbital Atherectomy System (OAS), Rotablator Rotational Atherectomy System, Magnetic Resonance Imaging (MRI); Device · Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Ischemia
Interventions: Percutaneous coronary intervention; Procedure
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Anterior Myocardial Infarction
Interventions: Abciximab local infusion, No local infusion, Thrombus aspiration; Drug · Other · Procedure
Lead sponsor: Atrium Medical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 7
States / cities: Takoma Park, Maryland • Charlotte, North Carolina • Greensboro, North Carolina + 4 more

Search by objective public record fields.

FAME II-10-year Follow-Up

Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus

The Prevalence of Radial Artery Occlusion in Diagnostic Cardiac Catheterization and Percutaneous Intervention

Impact of CTO PCI (Chronic Total Occlusion Percutaneous Intervention) on Regular Physical Activity

Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation

Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

The xDAPT External Validation Study

Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack

Aspirin Resistance and Percutaneous Coronary Intervention (PCI)

Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI

Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI)

Cardiac Rehab Referral Nudges

An Observational Study of Cholesterol in Coronary Arteries

HARMONEE - Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt

Physical Activity Telehealth Intervention After Percutaneous Coronary Procedures

XIENCE 28 USA Study

A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

PCI Alternative Using Sustained Exercise

Comparison of Orbital Versus Rotational Atherectomy Effects On Coronary Microcirculation in PCI

Intracardiac T-wave Alternans and Ischemia

The INFUSE - Anterior Myocardial Infarction (AMI) Study